Nantes, November 29, 2022 – 6 p.m. CET – Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotechnology company specializing in precision phage therapy intended to treat antibiotic-resistant and/or complicated bacterial infections, announces today that the company has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), for the continuation without modification of the phase II clinical study PhagoDAIR in bone and joint infections on prostheses caused by Staphylococcus aureus (S. aureus).
Didier Hoch, Chairman and CEO of Pherecydes Pharma, declares: “The positive recommendations of the DSMB confirm the good tolerance profile of our phages already observed during numerous compassionate treatments. We are delighted to be able to continue the PhagoDAIR study, which represents real hope for many patients suffering from bone and joint infections on prostheses caused by S. aureus. »
To receive all of Pherecydes Pharma’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.